Waxman Asks FDA To Explain How Its Regulatory Priorities Aid Public Health
This article was originally published in The Tan Sheet
Executive Summary
House Oversight and Government Reform Committee Chairman Henry Waxman is challenging FDA's priorities, saying the agency appears more interested in loosening marketing restrictions and reducing product liability for drug and device makers than in protecting public health